Research programme: allergic rhinitis therapeutics - Cornerstone TherapeuticsAlternative Names: CRTX 058; CRTX 070
Latest Information Update: 29 Mar 2012
At a glance
- Originator Cornerstone Therapeutics
- Mechanism of Action Cholinergic receptor modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Allergic rhinitis
Most Recent Events
- 31 Dec 2011 Discontinued - Preclinical for Allergic rhinitis in USA (unspecified route)